血管内皮生长因子VEGF单核苷酸多态性与同步放化疗后食管鳞癌患者预后关系的研究  

Polymorphisms in VEGF and Response to CRT in ESCC Patients

作　　者：裴忠玲[1] 郭卿[2,3] 孙新臣[1] 陈佳艳[1] 葛小林[1] 张胜[1] 宋亚颀[3] 张弛[1] 

机构地区：[1]江苏省人民医院放疗科,江苏南京210029 [2]泰州市人民医院肿瘤科,江苏泰州225499 [3]南京医科大学第一临床学院,江苏南京210068

出　　处：《四川医学》2015年第6期779-782,共4页Sichuan Medical Journal

摘　　要：目的研究血管内皮生长因子(vascular endothelial growth factor,VEGF)基因单核苷酸多态性(single nucleotide polymorphism,SNP)与同步放化疗后食管鳞癌患者预后的相关性。方法经病理学确诊的食管鳞癌患者100例,采用同步放化疗方案。治疗前采集入组患者空腹外周血,采用基因芯片法检测VEGF rs3025039及rs833061的SNP。随机抽取10%的样本行基因测序验证此方法的准确性,比较不同基因型食管鳞癌患者同步放化疗后生存期的差异。结果VEGF rs3025039及rs833061两个位点的基因型频率分布均符合Hardy-Weinberg平衡,且分布与年龄、性别并无关联。中位随访时间22个月,VEGF rs3025039 CT+CC基因型同步放化疗后食管鳞癌患者MST(Median survival time)、1年、2年和3年生存率为96.6%、71.4%、26.8%,均优于TT基因型患者60.0%、18.8%、9.42%,(P<0.05);VEGF rs833061 CC基因型患者同步放化疗后2年生存率(51.3%)优于CT+TT基因型患者(21.7%)(P<0.05)。两组间MST、1年和3年生存率无统计学差异(P>0.05)。结论 VEGF rs3025039及rs833061基因多态性与ESCC患者同步放化疗后的生存期存在相关性,是预测ESCC患者同步放化疗后生存期的潜在指标。Objective To investigate the association of the single nucleotide polymorphism（ SNP） of vascular endothelial growth factor （ VEGF） gene and overall survival in locally advanced esophageal squamous cell carcinoma （ ESCC） patients after re-ceiving concurrent chemoradiotherapy （ CRT） . Methods A total of 100 patients with ESCC were routinely treated by CRT. The polymorphie genotypes of VEGF rs3025039 and rs833061 were analyzed by gene-chip method. DNA samples were isolated from pe-ripheral blood before CRT. Furthermore, we extracted 10% samples randomly for accuracy of this method. To explored the associa-tion between SNP of VEGF rs3025039, rs833061 and prognosis to CRT in ESCC patients. Results Genotype distributions had no deviation from Hardy-Weinberg equilibrium. Median follow-up was 22 months. Median survival time（MST）, 1-year survival, 2-year survival and 3-year survival rates of ESCC patients with the VEGF rs3025039 CT ＋CC genotype and TT genotype were 26. 92 months, 96. 6%, 71. 4% and 26. 8% VS. 16. 54 months, 60. 0%, 18. 8% and 9. 42% （P〈0. 05）, respectively. Total-ly, 2-year survival of VEGF rs833061 CC genotype and CT＋TT genotype were 51. 3% VS. 21. 7% （P〈0. 05）, respectively. MST,1-year survival, and 3-year survival rates have no difference（P〉0. 05）. Conclusion Polymorphisms of VEGF rs3025039 and rs833061 might be associated with overall survival in ESCC patients after CRT, and they might be the predictive bio-markers for overall survival.

关 键 词：血管内皮生长因子 单核苷酸多态性 食管鳞癌 同步放化疗 生存期 

分 类 号：R735.1[医药卫生—肿瘤]